Clinical Research Directory

Inclusion Criteria: * Women and men between the ages 18-65 years. * Body mass index (BMI) between 18.5 and 35 kg/m2. * For female participants: No significant discomfort during pre-menses/menses. * Daily sleep duration between 7-9 hours, verified by electronic sleep diary data for two weeks. * Habitual sleep period must begin within one hour of 11:00pm (to ensure normal entrainment). * Negative toxicology screen, including: amphetamines, barbiturates, benzodiazepines, cocaine, opiates, and methadone. Toxicology screening will be performed as part of the screening lab tests; an outside lab toxicology screening will not suffice. Exclusion Criteria: * Active infection/disease. * Following blood chemistry values outside of the laboratory's normal range or the range specified below: * WBC (range: 2.0-10.0 K/uL) * Platelet count * Hematocrit in range * TSH outside of the laboratory's normal range * Bilirubin \>1.5 upper limit of normal * ALT or AST \>2.5 upper limit of normal * Stage 4 chronic kidney disease based on CKD epi-equation * Pre-diabetes or diabetes (HbA1c \>5.7%) * History of neurological, chronic pain, immune/inflammatory, vascular/cardiovascular (including Raynaud syndrome), liver/kidney, metabolic disorders (including diabetes). * Current asthma (diagnosis of asthma and either asthma symptoms present within the past years or taking medication for asthma) and/or history of ASA induced sensitivity * Systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg prior to the initial and medical screens. Systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg during admissions (Stays 1, 2, and 3) * History of gastrointestinal disorders, including esophageal reflux, gastric and duodenal ulcers, gastrointestinal bleeding. * Personal or family (first degree relative) history of any stroke * History of psychiatric disorders, including major depressive disorders, bipolar disorders, panic disorders, post-traumatic stress disorders (PTSD), thought disorders, and substance abuse/dependence disorders. * History of intolerance or allergy to non-steroidal anti-inflammatory drugs (NSAID). * Sleep disorders: Sleep efficiency \<80% based on polysomnographic (PSG) screening night; respiratory disturbance index of \>10 events/hour based on PSG screening night, periodic leg movement index (PLMI) of \>25/hour and/or PLMAI (PLM arousal index) of \>5/hour based on PSG screening night; restless legs syndrome, circadian rhythm disorders, and nightmare disorders determined by diagnostic interview. * Pregnant/nursing. * Regular medication use other than oral contraceptives. * Intake of non-steroidal anti-inflammatory drugs (NSAIDs) or cold/cough remedies within the last month. * Intake of dietary supplements containing DHA/EPA-derived fatty acids (e.g., fish oil) within the last 3 months prior to study start. * Donation of blood or platelets within three months prior to or in-between study arms. * Smoking.